| |
ALL PATIENTS
|
TP-TREATED GROUP
|
PC/PAC-TREATED GROUP
|
|---|
| |
N = 435
|
N = 191
|
N = 244
|
|
Age (years)
| | | |
|
Range
|
20-78
|
20-78
|
24-77
|
|
Mean
|
54.3
|
54.9
|
53.9
|
|
FIGO stage
| | | |
|
IIB, IIC
|
27 (6%)
|
10 (5%)
|
17 (7%)
|
|
IIIA, IIIB
|
82 (19%)
|
26 (14%)
|
56 (23%)
|
|
IIIC
|
277 (64%)
|
136 (71%)
|
141 (58%)
|
|
IV
|
49 (11%)
|
19 (10%)
|
30 (12%)
|
|
Residual tumour size
| | | |
|
0
|
87 (20%)
|
35 (18%)
|
52 (21%)
|
|
≤ 2 cm
|
141 (32%)
|
77 (40%)
|
64 (26%)
|
|
> 2 cm
|
207 (48%)
|
79 (42%)
|
128 (53%)
|
|
Histological type
| | | |
|
serous
|
334 (77%)
|
142 (74%)
|
192 (79%)
|
|
endometrioid
|
22 (5%)
|
8 (4%)
|
14 (6%)
|
|
clear cell
|
15 (3%)
|
4 (2%)
|
11 (4%)
|
|
undifferentiated
|
33 (8%)
|
20 (11%)
|
13 (5%)
|
|
other types
|
31 (7%)
|
17 (9%)
|
14 (6%)
|
|
Histological grade
| | | |
|
G 2
|
54 (13%)
|
24 (12%)
|
30 (12%)
|
|
G 3
|
263 (60%)
|
110 (58%)
|
153 (63%)
|
|
G 4
|
118 (27%)
|
57 (30%)
|
61 (25%)
|
|
Response to chemotherapy
| | | |
|
complete remission
|
257 (59%)
|
124 (65%)
|
133 (55%)
|
|
partial remission/no change
|
112 (26%)
|
62 (32%)
|
50 (20%)
|
|
progression
|
66 (15%)
|
5 (3%)
|
61 (25%)
|
|
Platinum sensitive
|
129 (30%)
|
65 (34%)
|
64 (26%)
|
|
Highly platinum sensitive
|
83 (19%)
|
40 (21%)
|
43 (18%)
|
|
Platinum resistant
|
223 (51%)
|
86 (45%)
|
137 (56%)
|
|
Number of patients at risk (OS)
| | | |
|
1 year
|
389 (89%)
|
180 (94%)
|
209 (86%)
|
|
2 years
|
276 (63%)
|
141 (74%)
|
135 (57%)
|
|
3 years
|
172 (39%)
|
83 (43%)
|
89 (36%)
|
|
4 years
|
116 (27%)
|
53 (28%)
|
63 (26%)
|
|
5 years
|
76 (17%)
|
31 (16%)
|
45 (18%)
|
|
Number of patients at risk (DFS)
| | | |
|
1 years
|
143 (56%)
|
70 (56%)
|
73 (55%)
|
|
2 years
|
83 (32%)
|
40 (32%)
|
43 (32%)
|
|
3 years
|
61 (24%)
|
27 (22%)
|
34 (26%)
|
|
4 years
|
43 (17%)
|
17 (14%)
|
26 (19%)
|
|
5 years
|
28 (11%)
|
10 (8%)
|
18 (13%)
|
|
Follow-up time
| | | |
|
Range (month)
|
4.4-198.3
|
4.8-100.6
|
4.4-198.3
|
|
mean
|
30
|
32.2
|
27.5
|
|
Outcome
| | | |
|
NED
|
45 (10%)
|
27 (14%)
|
18 (7%)
|
|
AWD
|
45 (10%)
|
35 (18%)
|
10 (4%)
|
|
DOD
|
335 (77%)
|
124 (65%)
|
211 (87%)
|
|
DOC
|
10 (3%)
|
5 (3%)
|
5 (2%)
|
- PC- cyclophosphamide and cisplatin, PAC-PC plus doxorubicin, TP-taxane-platinum therapy; NED-no evidence of disease, AWD-alive with disease, DOD-died of disease, DOC-died of other causes; OS-overall survival, DFS-disease free survival
